SeraCare Makes Key Investment in Expanding R&D Facility; Strengthens Leadership with New Hires

MILFORD, Mass., June 19, 2015 /PRNewswire/ -- SeraCare Life Sciences, a leading partner to global In Vitro Diagnostics manufacturers, announced today an expansion and upgrade to their Gaithersburg, MD, R&D facility. With strategic investments to expand laboratory and manufacturing space, this new Molecular Diagnostics Center of Excellence for product development and manufacturing will now also provide digital PCR, Next Generation Sequencing (NGS) technologies and bioinformatics resources to help accelerate the company's goal of enabling precision medicine.

"SeraCare is fully committed to enabling precision medicine through the development of innovative technologies and tools. These new investments in both infrastructure and top notch talent at our Gaithersburg R&D facility are key in allowing us to develop ground-breaking solutions to support the safe and effective expansion of precision-driven diagnostics," says Charlie Mamrak, CEO, SeraCare Life Sciences.

The company is also pleased to announce the hiring of Dale Yuzuki, Director of Market Development, Precision Oncology and Ram Santhanam, Director of Market Development, Reproductive Health.

Dale comes to SeraCare most recently from Life Technologies/Thermo-Fisher Scientific Corp. where he was a Senior Market Development Manager and was instrumental in developing online scientific content supporting their genetic analysis portfolio including NGS.

Ram comes to SeraCare from RainDance Technologies where he was a Global Sales Account Manager for their novel droplet-based technologies for the NGS market.

"We are thrilled to welcome Ram and Dale to our growing team. As thought leaders in the industry, they both bring a deep understanding of precision medicine technologies and will significantly add to our partnering capability," says Mamrak.

About SeraCare Life Sciences, Inc.

SeraCare enables the promise of precision medicine by advancing the understanding of disease and providing assurance of the diagnostic result.  Our innovative tools and technologies not only ensure the safe, effective, and accurate performance of diagnostic assays but also establish a framework for regulating, compiling, and interpreting data from precision diagnostics.  Our portfolio includes a broad range of products such as quality control technologies, disease-state specimens and tissues for research and development, processed biological materials, and immunoassay reagents. SeraCare is a Linden Capital Partners portfolio company.  For more information, please visit www.seracare.com and follow SeraCare on Twitter (@SeraCare).

SOURCE SeraCare Life Sciences

Related Links

http://www.seracare.com